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Documentation of CHD risk factors also showed an increased trend from 18% to 37% but this 
difference did not achieve statistical significance (p value 0.07). Importantly, the percentage of 
primary prevention patients who underwent lipid monitoring increased significantly from 59% to 
90% (p value <0.001). Percentage of patients with LDL at goal increased to 78% and appropriate 
aspirin prophylaxis increased to 76% but neither result achieved statistical significance.  
 
CONCLUSIONS: 
A quality improvement process to improve the primary prevention of CHD at the UMHC 
outpatient internal medicine resident clinic achieved a significant increase in FRS documentation 
through resident education and quick reference postings.  This improvement significantly increased 
incidence of lipid monitoring and showed a trend towards increasing the percentage of patients with 
LDL at goal and on appropriate aspirin prophylaxis. Repeated cycles of quality improvement and 
hard changes to the electronic medical record are needed to achieve the stated goal of FRS 
documentation and significantly increase the adherence to ATPIII and USPSTF guidelines for CHD 
prevention. 
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Introduction: 
Despite advancement of neurotechnology and neuroimaging, detailed history and examination 
remain the most important tools for diagnosis of unilateral headache and orbital pain. Headache is a 
common symptom among all age groups with a considerable array of differential diagnoses. Tolosa 
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Hunt syndrome is a rare cause of unilateral headache and orbital pain. High clinical suspicion based 
on clinical presentation, thorough history and physical examination is crucial for diagnosis. 
  
Case presentation: 
A 65-year-old male patient presented with 2-3 month history of excruciating, sharp, left-sided 
headache and orbital pain involving the ipsilateral forehead, eye and cheek above the upper jaw, 
which did not cross the midline. It had a gradual onset, starting as mild intermittent pain and 
progressing to a continuous pain with frequent spikes lasting 4-6 hours each.  These attacks became 
more frequent and intense during the two weeks prior to presentation. The pain was not affected by 
posture and did not radiate. It was, however, associated with photophobia, phonophobia, ipsilateral 
conjunctival redness and tearing, nasal discharge and hypersensitivity to touch over the distribution 
of pain. There were no clear relieving factors. There was no history of recurrent headaches, fever, 
neck rigidity, jaw claudication, scalp necrosis, skin rash, blurring of vision, double vision, facial 
asymmetry, limb weakness or numbness or other localizing symptoms. 
  
Physical examination revealed mild left upper eyelid ptosis, eyelid swelling, conjunctival erythema, and 
tearing.  There was mild weakness of the lateral rectus muscle on abduction suggesting mild left 
abducens nerve palsy and hyperesthesia over the left ophthalmic and maxillary nerve distribution. 
The pupils were symmetric in size and reactivity.  The examination was otherwise unremarkable, 
including funduscopic examination and remaining extraocular motility.  Anhidrosis was not 
appreciated.   
  
The differential diagnoses initially considered were daily persistent headache, ophthalmoplegic 
migraine, cluster headache, hemicrania continua, trigeminal neuralgia, temporal arthritis, early herpes 
zoster (HZV), diabetic neuropathy, Horner’s syndrome secondary to mass or carotid dissection, 
and cavernous sinus thrombosis or tumor. 
  
Laboratory studies including Complete Blood Count, Comprehensive Metabolic Panel, Thyroid 
Stimulating Hormone, Angiotensin-Converting Enzyme level, Hemoglobin A1C, HZV serology, C-
Reactive Protein, and vasculitis screen including ANA were normal. The Westergren Erythrocyte 
Sedimentation Rate (ESR) was minimally elevated at 40 mm/hr (normal 0-20 mm/hr). Chest X-Ray, 
Head and Neck CT scan, CT angiography with venous phase and MRI also were normal. Temporal 
artery biopsy was declined by the patient. 
  
The patient was treated with numerous analgesics including narcotics and Non-Steroidal Anti-
Inflammatory Drugs, and additionally he received 100% oxygen which did not alleviate his pain. 
  
Based on distribution of the pain, duration, evidence of involvement of cavernous sinus structures 
including hyperesthesia over left ophthalmic and maxillary nerve distribution, left abducens nerve 
palsy and ptosis likely secondary to involvement of oculomotor/sympathetic fibers around carotid 
artery and exclusion of other causes, Tolosa Hunt syndrome was proposed. High dose intravenous 
glucocorticoids were initiated and the patient improved dramatically within 12 hours of treatment. 
  
Discussion: 
Tolosa Hunt Syndrome (THS) is a rare cause of painful ophthalmoplegia caused by idiopathic 
noncaseating granulamatous or nongranulomatous inflammation of the cavernous sinus or superior 
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orbital fissure.1,2  It is a part of a continuum of idiopathic orbital inflammation, also known as 
idiopathic orbital pseudotumor, with which it shares histopathological and clinical features, and is 
distinguished only by its unique anatomic localization to the cavernous sinus. THS has an estimated 
incidence of 1 per million per year, affecting any age group, but is rare before the age of 20.1,2 
  
Clinically, THS is characterized by acute onset unilateral, rarely bilateral, periorbital pain that is 
described as “severe,” “intense,” or “lancinating.” It often resolves spontaneously but tends to have 
episodes of relapse and remission.3  
 
The pain frequently extends into retro-orbital, frontal and temporal regions and features of 
cavernous sinus structure involvement may provide clues to diagnosis.  Key signs include ophthalmic 
and maxillary nerve involvement manifesting as facial paresthesia and loss of corneal reflex, cranial 
nerves III, IV, VI involvement evidenced by ophthalmoplegia, diplopia, miosis and ptosis, sympathetic 
fiber involvement appearing as ptosis with or without features of orbital involvement such as lid 
swelling, proptosis, orbital pain and vision loss. There is no pathognomonic feature of THS and all 
these signs can be seen with other cavernous sinus pathology such as thrombosis, tumor, fistula or 
infections. Furthermore, THS can mimic temporal arteritis especially if the pain occurs before cranial 
nerve involvement and ESR is elevated (which is seen in 45% of THS cases). On the other hand, eye 
pain, diplopia and cranial nerve involvement are rare in temporal arteritis.9 Accordingly, THS is a 
diagnosis of exclusion.1,4 Extracavernous extension of inflammation has been infrequently reported in 
the form of mandibular and facial nerve involvement, but no systemic involvement has been 
reported.2,3,5 
  
While THS is considered a benign condition, permanent neurologic deficits like vision loss and 
cranial nerve palsies do occur, and relapses are common, often requiring prolonged 
immunosuppressive therapy.1,2,3 
  
The International Journal of Headache/International Classification of Headache Disorders 2nd 
edition (ICHD-2) criteria for THS include:4  
 One or more episodes of unilateral orbital pain persisting for weeks if left untreated. 
 Paresis of one or more of the third, forth, and/or sixth cranial nerves and/or 
demonstration of granuloma by MRI or biopsy. 
 Paresis coincides with the onset of pain or follows it within 2 weeks. 
 Pain and paresis resolve within 72 hours when treated adequately with glucocorticoid. 
 Other causes have been excluded by appropriate investigations. 
 
Although painful ophthalmoplegia is a feature of THS, most patients (over 75 percent) who present 
with painful ophthalmoplegia do not have THS.2  Diagnostic testing, including neuroimaging by 
angiography and MRI brain and orbit should be performed to rule out other causes.1,2  Thin-slice high
–magnetic field MRI of the cavernous sinus with fat-suppressed cuts of the orbits is the modality of 
choice looking for typical inflammatory changes in the cavernous sinus, superior orbital fissure, and/
or orbital apex. MRI findings of THS include enlargement of the cavernous sinus with abnormal 
tissue, abnormal convexity of the wall of the cavernous sinus and focal narrowing of the 
intracavernous internal carotid artery.2  However, these findings are not specific to THS and normal 
images do not exclude the diagnosis.1,2,3  Based on MRI findings, THS can be classified as benign with 
normal MRI scan, and inflammatory with classic inflammatory features on MRI scans.6  In a meta-
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analysis, approximately one-third of clinically defined THS had normal MRI findings, but a defined MR 
protocol has yet to be determined.7  Reliable detection is complicated by the fact that differentiation 
of the normally enhancing venous space in the sinus from the contrast enhancement of granulomas 
may be limited with the conventional spin echo MRI and thus requires specific imaging modalities.8   
  
Biopsy of the lesion may be required to confirm the diagnosis; however, the technical difficulty of 
cavernous sinus region biopsies limits its usefulness.  Instead, a trial of glucocorticoids is usually 
performed and rapid response with dramatic decrease in pain occurs.  More aggressive testing, 
including biopsy and CSF evaluation, to exclude other causes is recommended if symptoms are 
progressing, atypical or recurrent.  This is particularly the case if the patient has failed treatment with 
glucocorticoids or if glucocorticoid efficacy is lost soon after an initial response.1,2 Even with careful 
adherence to clinical criteria and diagnostic evaluation, misdiagnosis can still occur; consequently, 
follow-up is required to exclude other causes of painful ophthalmoplegia.2,4 
  
Glucocorticoids have altered the course of the disease by providing significant pain relief within 24-
72 hours of therapy initiation.  However, there are no clinical data as to whether glucocorticoids 
hasten recovery of associated cranial nerve palsies.1,3 Additionally, no standard dose or duration has 
been indicated in literature.  A dose of 1mg/kg/day of methylprednisone tapered slowly was well 
received.5 
  
Although the glucocorticoid trial is instructive, an initial clinical or MRI response is not diagnostic 
since other entities, such as lymphoma and vasculitis, also may respond clinically and radiographically 
to glucocorticoid therapy.2,3 
  
Ophthalmoparesis usually requires weeks to months for resolution.6  In some cases, the 
ophthalmoparesis may not completely resolve depending on the degree of inflammation and the 
aggressiveness of therapy. For refractory cases, azathioprine, methotrexate, or radiation therapy has 
been employed.1 
 
Recurrences occur in about one-half of reported patients over an interval of months to years.2 
Ipsilateral, contralateral, and bilateral relapses have been reported. Relapses require repeated 
investigations to rule out inflammatory and neoplastic disorders such as sarcoidosis, Wegener's 
granulomatosis, and lymphoma.2 
 
Conclusion: 
THS is a rare cause of relapsing remitting painful ophthalmoplegia and unilateral headache secondary 
to idiopathic inflammation of cavernous sinus, superior orbital fissure, or both.  THS can mimic many 
other conditions.  A dramatic response to systemic glucocorticoids is helpful in the diagnosis.  An 
MRI scan is the modality of choice for investigation, but the absence of MRI findings does not exclude 
THS. High index of suspicion and close follow up are important for accurate diagnosis. 
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High Vitamin B12 Level 
 
Puja Nistala, MD 
Chief Fellow, Division of Hematology-Oncology 
Ellis Fischel Cancer Center 
University of Missouri-Columbia  
 
 
Vitamin B12/cobalamin functions as an important co-enzyme in the human body and is essential for 
purine and pyrimidine synthesis. Vitamin B12 deficiency is a very well recognized clinical entity but the 
conditions leading to elevated levels of vitamin B12 are generally not; hence the purpose of this article 
is to discuss such etiologies. Understanding the mechanisms will necessitate a brief review of vitamin 
B12 metabolism, presented below.  
 
Under normal physiological conditions, dietary cobalamin binds to haptocorrin (HC) in saliva to be 
transported to the duodenum where free cobalamin is released. The free cobalamin in the duodenum 
binds to intrinsic factor (IF) forming a complex which is taken up by the intestinal mucosa to be 
ultimately released into the circulation. The majority of cobalamin in circulation is bound to 
haptocorrin (HC) and only a small portion (5-20%) is bound to transcobalamin (TC II). The plasma half
-life (t ½) of TC II is short, only 40min-5hrs, whereas it is a long, 6-9 days for HC. When 
transcobalamin passes through enterohepatic circulation it is taken up by the liver for storage and is 
later released into bile.  
 
 
 
 
 
 
 
 
 
 
The reference range for vitamin B12 levels is 200-900 pg/mL (picograms per milliliter) and elevated 
cobalamin levels can be seen in various malignancies including hematological conditions like 
myeloproliferative disorders, renal and liver disorders. 
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Bound protein/form Transcobalamin (TCII)  Haptocorrin (HC) 
Plasma t ½  40min-5hrs 6-9 days 
Site of synthesis Liver, intestine, endothelium Salivary glands, gastric mucosa 
